- Previous Close
15.10 - Open
15.40 - Bid 15.00 x 100
- Ask 15.60 x 624100
- Day's Range
14.70 - 15.70 - 52 Week Range
9.00 - 32.00 - Volume
3,051,835 - Avg. Volume
2,765,668 - Market Cap (intraday)
181.029M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.06 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is based in Haifa, Israel.
bonus-bio.comRecent News: BONS.TA
View MorePerformance Overview: BONS.TA
Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BONS.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BONS.TA
View MoreValuation Measures
Market Cap
177.52M
Enterprise Value
179.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
20.22
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.88%
Return on Equity (ttm)
-99.82%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.19M
Diluted EPS (ttm)
-0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
14.14M
Total Debt/Equity (mrq)
69.65%
Levered Free Cash Flow (ttm)
-13.44M